Daily Endocrinology Research Analysis
Analyzed 73 papers and selected 3 impactful papers.
Summary
Three studies stand out in endocrinology: a secondary analysis of two randomized crossover trials shows dulaglutide suppresses copeptin, implicating GLP-1 signaling in vasopressin regulation; a genome-wide meta-analysis with Mendelian randomization links circulating pro-neurotensin to structural and functional brain changes relevant to obesity; and a clinical assay validation robustly identifies insulin receptor autoantibodies in Type B insulin resistance with high diagnostic accuracy.
Research Themes
- GLP-1 modulation of vasopressin and fluid homeostasis
- Gut–brain–metabolic axis: pro-neurotensin and obesity neurobiology
- Autoimmune insulin receptoropathies: diagnostic assay validation
Selected Articles
1. Effects of GLP-1 Receptor Agonists on Copeptin in Euvolemic Participants.
Across two double-blind randomized crossover trials (n=54), 3 weeks of dulaglutide 1.5 mg weekly significantly reduced morning copeptin by 12% versus placebo (median within-subject difference −0.7 pmol/L; p=0.047). Effects on copeptin were independent of changes in blood pressure, BMI, or nausea, suggesting GLP-1–mediated inhibition of the vasopressin system and a mechanistic link to sodium and water balance.
Impact: This is the first controlled evidence that a GLP-1 receptor agonist suppresses a vasopressin surrogate (copeptin) in euvolemic humans, advancing understanding of incretin effects on fluid homeostasis.
Clinical Implications: Clinicians should be aware that GLP-1 RAs may suppress vasopressin activity; monitoring of fluid balance and electrolytes may be prudent in patients with disorders of water homeostasis (e.g., primary polydipsia, chronic kidney disease) or on concomitant diuretics.
Key Findings
- Dulaglutide reduced copeptin by a median of 0.7 pmol/L (12%) versus placebo after 3 weeks (p=0.047).
- The copeptin reduction did not correlate with changes in blood pressure, BMI, or nausea.
- The finding supports GLP-1–mediated inhibition of the vasopressin system under euvolemic conditions.
Methodological Strengths
- Pooled analysis of two randomized, double-blind, placebo-controlled crossover trials
- Standardized timing of sampling (08:00) and within-subject comparison increasing power
Limitations
- Secondary analysis with a short 3-week treatment duration per phase
- Modest sample size and limited to euvolemic participants; no direct AVP measurements
Future Directions: Test GLP-1–vasopressin interactions in broader populations (hyponatremia, heart failure, CKD), include direct AVP assays, assess dose-response and longer-term effects, and evaluate clinical endpoints (polyuria, serum sodium).
OBJECTIVE: Glucagon-like Peptide-1 (GLP-1) plays an important modulatory role in sodium and water homeostasis. Recent studies demonstrated that long-term treatment with GLP-1 receptor agonists (RAs) reduces fluid intake and urine output. To our knowledge, no direct effect of GLP-1 on vasopressin has been observed. This secondary analysis aimed to investigate changes in copeptin levels in euvolemic participants treated with the GLP-1 RA dulaglutide versus placebo. DESIGN: Secondary analysis of two randomized, double-blind, placebo-controlled, cross-over trials in 34 patients with primary polydipsia and 20 healthy participants. METHODS: Participants received a 3-week intervention with dulaglutide (Trulicity) 1.5 mg or placebo (0.9% sodium chloride) subcutaneously once weekly. Blood for copeptin analysis was collected at 08:00 after each treatment phase. To estimate the treatment effect of dulaglutide, we derived the absolute within-subject differences of copeptin between dulaglutide and placebo and used the Wilcoxon rank test for statistical analysis. RESULTS: All 54 participants of the two cross-over trials were included. Median age was 27 years (IQR, 24-37.5 years), 63% were female. Median BMI was 23 kg/m2 (IQR, 20.8-24.8). After 3-week treatment, dulaglutide was associated with a significant suppression of copeptin with a median within-subject difference of -0.7 pmol/L (p=0.047), corresponding to a 12% reduction compared to placebo. Treatment-induced changes in copeptin were not significantly correlated with GLP-1-mediated reductions in blood pressure, BMI, or incidence of nausea. CONCLUSIONS: Our analysis provides evidence that the GLP-1-RA dulaglutide inhibits the vasopressin system and proposes physiological mechanisms that may explain the role of GLP-1 in sodium and water balance.
2. Genetic dissection of serum pro-neurotensin suggests potential causal impact on brain structure.
In a 10,096-person GWAS meta-analysis, three loci were associated with circulating pro-neurotensin. Mendelian randomization suggested causal effects of higher pro-NT on subcortical structures (pallidum, brainstem), and MRI network analyses showed reduced reward network coherence in carriers of alleles linked to higher pro-NT, pointing to a gut–brain mechanism contributing to obesity.
Impact: This integrative human genetics–neuroimaging study provides causal evidence linking a metabolic peptide precursor to brain structure and function, advancing the gut–brain understanding of obesity.
Clinical Implications: Pro-neurotensin may serve as a biomarker for obesity risk stratification and a potential therapeutic target; however, interventional studies are needed before clinical adoption.
Key Findings
- Identified three genome-wide significant loci (chr4 rs6822751, chr11 rs41392245, chr12 rs2723889) for circulating pro-neurotensin.
- Mendelian randomization indicated causal links between higher pro-NT and structural variation in pallidum and brainstem.
- MRI analyses showed reduced reward network coherence in alleles associated with higher pro-NT levels.
Methodological Strengths
- Large multi-cohort GWAS meta-analysis with Mendelian randomization for causal inference
- Independent neuroimaging validation (MRI subset, network coherence analyses)
Limitations
- Predominantly European ancestry limits generalizability
- Mendelian randomization assumptions and modest effect sizes; no interventional confirmation
Future Directions: Extend analyses to diverse ancestries, explore longitudinal brain changes, and test whether modifying pro-NT signaling alters neurobehavioral and metabolic outcomes.
BACKGROUND: Pro-neurotensin (pro-NT) is the stable circulating precursor of neurotensin (NT), a neuropeptide expressed mainly in the central nervous system and small intestine that regulates key physiological processes like fatty acid absorption in the gut and suppresses appetite via central mechanisms. Studies in NT-deficient mice and humans implicate NT in obesity and insulin resistance, highlighting its role in metabolic regulation. METHODS: To explore the genetic determinants of circulating pro-NT and its causal relationships with obesity and brain phenotypes, we conducted a genome-wide meta-analysis of serum pro-NT levels in 10,096 individuals of European ancestry across four independent cohorts. We further examined causal effects of pro-NT on brain structures and function using Mendelian Randomisation (MR) and analysed brain magnetic resonance imaging (MRI) data from a subset (N = 1090) of the LIFE-Adult cohort. FINDINGS: Three genome-wide significant loci associated with serum pro-NT were identified on chromosomes 4 (rs6822751), 11 (rs41392245), and 12 (rs2723889). MR analyses revealed causal links between elevated pro-NT and structural variation in selected subcortical brain regions, notably the pallidum and brainstem. MRI analyses in the LIFE-Adult subset showed reduced reward network coherence in alleles linked to higher pro-NT levels, suggesting a potential neural mechanism contributing to obesity. INTERPRETATION: These findings suggest a potential causal relationship between serum pro-NT levels and variance in structural brain phenotypes that could be implicated in obesity. FUNDING: See Acknowledgements. Key funding bodies: Deutsches Zentrum für Diabetesforschung (DZD, Grant: 82DZD06D03) to MSt; European Union, by the European Regional Development Fund (ERDF) to RB; Swedish Foundation for Strategic Research (IRC LUDC), Swedish Research Council (SFO-EXODIAB), Swedish Research Council (AIR Lund- Artificially Intelligent use of Registers at Lund University, VR; Grant No. 2019-61406) to OM.
3. Insulin Receptor Family Autoantibodies in Patients with Type B insulin Resistance.
A receptor-specific immune-luminometric assay for insulin receptor autoantibodies achieved excellent diagnostic performance (AUC 0.96; 91.3% sensitivity, 93.9% specificity) for Type B insulin resistance. InsR-aAb titers correlated strongly with hyperglycemia and low IGF-1 z-scores, and IRRR autoantibodies associated with reduced bicarbonate, refining diagnostic pathways and pathophysiologic insight.
Impact: Provides validated, clinically deployable diagnostics for a rare but severe endocrine disorder and uncovers novel IRRR autoantibody associations with acid–base parameters.
Clinical Implications: In suspected Type B insulin resistance, clinicians can use a validated immune-luminometric InsR-aAb assay and apply the defined cutoff to distinguish autoimmune from non-autoimmune IR, informing immunosuppressive therapy decisions.
Key Findings
- InsR autoantibody assay showed AUC 0.96 with 91.3% sensitivity and 93.9% specificity for TBIR.
- Higher InsR-aAb titers correlated with higher HbA1c, glucose, insulin and lower IGF-1 z-scores (all p<0.0001).
- IRRR autoantibodies associated with lower bicarbonate (p=0.04), suggesting links to acid–base regulation.
Methodological Strengths
- Receptor-specific immune-luminometric assays with ROC-based diagnostic evaluation
- Multivariate regression linking autoantibody titers to metabolic and acid–base biomarkers
Limitations
- Cross-sectional design limits causal inference and temporal dynamics
- Assay thresholds require external validation and availability may be limited
Future Directions: Prospective validation across centers, functional characterization of IRRR-aAb, and studies testing whether assay-guided immunotherapy improves outcomes.
OBJECTIVE: Type B insulin resistance (TBIR) is a rare autoimmune disorder characterized by insulin resistance (IR) secondary to insulin receptor autoantibodies (InsR-aAb). A paucity of clinical InsR-aAb assays and incomplete mechanistic understanding complicate diagnosis. This study aimed to (1) validate clinical performance of an immune-luminometric InsR-aAb assay in a relatively large cohort; (2) evaluate its diagnostic accuracy and define thresholds for TBIR diagnosis; (3) evaluate autoantibody profiles against InsR, type 1 IGF receptor (IGF-1R), and the insulin receptor-related receptor (IRRR) in TBIR and non-autoimmune IR. RESEARCH DESIGN AND METHODS: We conducted a cross-sectional analysis of patients with TBIR and non-autoimmune IR. InsR-aAb, IGF-1R-aAb, and IRRR-aAb titers were measured using receptor-specific immune-luminometric assays. ROC analyses assessed diagnostic performance of the InsR-aAb assay. Multivariate regression models evaluated associations between autoantibody titers and biomarkers of glycemia (HbA1c, glucose, insulin), growth (IGF-1 z-score [IGF-1z]), and pH regulation (bicarbonate, urine pH). RESULTS: In TBIR, higher InsR-aAb titers associated with increased HbA1c, glucose, insulin, and lower IGF-1z (all p<0.0001); higher IRRR-aAb titers with lower CO₂ (p=0.04). An optimal InsR-aAb cutoff for distinguishing TBIR from non-autoimmune IR was determined (AUC 0.96, sensitivity 91.3%, specificity 93.9%). In non-autoimmune IR, autoantibody titers were not associated with glycemia biomarkers; IGF-1z increased with mild IR (p=0.005) and decreased with severe IR (p=0.01). CONCLUSION: This study validates an InsR-aAb assay in the largest TBIR cohort to date and identifies a novel association between IRRR-aAb and bicarbonate excretion. While InsR-aAb were detected in other IR disorders, pathogenic effects were specific to TBIR.